Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma.

被引：0
|
作者：
Palumbo, A [1 ]
Giaccone, L [1 ]
Bertola, A [1 ]
Bringhen, S [1 ]
Rus, C [1 ]
Triolo, S [1 ]
Pileri, A [1 ]
Boccadoro, M [1 ]
机构：
[1] Univ Turin, Sezione Ematol, Dipartimento Oncol, Turin, Italy
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5004
引用
收藏
页码：292B / 292B
页数：1
相关论文
共 50 条
  • [31] Thalidomide with dexamethasone for resistant multiple myeloma.
    Weber, DM
    Rankin, K
    Gavino, M
    Delasalle, K
    Alexanian, R
    BLOOD, 2000, 96 (11) : 167A - 167A
  • [32] SALVAGE THERAPY WITH BORTEZOMIB AND DEXAMETHASONE IN VERY ELDERLY PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
    Castelli, R.
    Pantaleo, G.
    Gallipoli, P.
    Arquati, M.
    Wu, M. A.
    Deliliers, G. Lambertenghi
    Cicardi, M.
    HAEMATOLOGICA, 2015, 100 : 740 - 740
  • [33] Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma
    Kauer, Joseph
    Sester, Lilli Sophie
    Kriegsmann, Katharina
    Weinhold, Niels
    Ober, Michael
    Mueller-Tidow, Carsten
    Goldschmidt, Hartmut
    Raab, Marc-Steffen
    Sauer, Sandra
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (03) : 453 - 462
  • [34] Thalidomide alone or with dexamethasone for multiple myeloma.
    Weber, DM
    Gavino, M
    Delasalle, K
    Rankin, K
    Giralt, S
    Alexanian, R
    BLOOD, 1999, 94 (10) : 604A - 604A
  • [35] Phase II study of thalidomide with dexamethasone for relapsed/refractory multiple myeloma
    Kinoshita, T
    Ohno, T
    Yuge, M
    Hiraga, J
    Matsushita, T
    Ando, S
    Naoe, T
    ANNALS OF ONCOLOGY, 2005, 16 : 206 - 206
  • [36] Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma
    Gordan Srkalovic
    Paul Elson
    Beth Trebisky
    Mary Ann Karam
    Mohamad A. Hussein
    Medical Oncology, 2002, 19 : 219 - 226
  • [37] Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma
    Srkalovic, G
    Elson, P
    Trebisky, B
    Karam, MA
    Hussein, MA
    MEDICAL ONCOLOGY, 2002, 19 (04) : 219 - 226
  • [38] Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma.
    Wang, Michael
    Knight, Robert
    Dimopoulos, Melitios
    Siegel, David
    Vincent Rajkumar, S.
    Facon, Thierry
    Alexanian, Raymond
    Yu, Zhinuan
    Zeldis, Jerome
    Olesnyckyj, Marta
    Weber, Donna
    BLOOD, 2006, 108 (11) : 1014A - 1015A
  • [39] Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed/refractory multiple myeloma.
    Monge, Jorge
    Kortuem, K. Martin
    Stewart, A. Keith
    Bergsagel, P. Leif
    Mikhael, Joseph
    Reeder, Craig B.
    Mayo, Angela
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Wakabayashi, Masashi
    Tsukasaki, Kunihiro
    Miyamoto, Kenichi
    Maruyama, Dai
    Yamamoto, Kazuhito
    Takatsuka, Yoshifusa
    Kusumoto, Shigeru
    Kuroda, Junya
    Ando, Kiyoshi
    Kikukawa, Yoshitaka
    Masaki, Yasufumi
    Kobayashi, Miki
    Hanamura, Ichiro
    Asai, Hiroaki
    Nagai, Hirokazu
    Shimada, Kazuyuki
    Tsukamoto, Norifumi
    Inoue, Yoshiko
    Tobinai, Kensei
    CANCER SCIENCE, 2018, 109 (05) : 1552 - 1561
12345